A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Inclusion Criteria:

• Documented diagnosis of Myelodysplastic syndrome, Acute myeloid leukemia, Non-acutepromyelocytic leukemia, Chronic myelomonocytic leukemia, Philadelphia-negativemyeloproliferative neoplasms, Myelodysplastic syndrome Myeloproliferative neoplasmsoverlap, Accelerated phase and blast phase Myeloproliferative neoplasms, Blasticplasmacytoid dendritic cell neoplasm according to the World Health Organization (WHO) 2016 classification

• Life expectancy of ≥ 3 months

• Stable renal function without dialysis for at least 2 months prior toinvestigational product administration

• Has moderate or severe hepatic impairment as defined by National Cancer InstituteOrgan Dysfunction Working Group criteria

Exclusion Criteria:

• Chemotherapy or radiotherapy within 2 weeks or 5 half-lives, whichever is longer,prior to the first day of investigational product administration

• Persistent, clinically significant non-hematologic toxicities from prior therapieswhich have not recovered to < Grade 2

• Any condition including the presence of laboratory abnormalities, which places theparticipant at unacceptable risk if he/she were to participate in the study

• History of inflammatory bowel disease, celiac disease, prior gastrectomy, gastricbypass, upper bowel removal, or any other gastrointestinal disorder or defect thatwould interfere with the absorption of the investigational product and/or predisposethe participant to an increased risk of gastrointestinal toxicity

Other protocol-defined inclusion/exclusion criteria apply